Ollin Biosciences raises $330.0M Series B (United States, Jun 2026)
$330.0M
$330 millionGenerated social card
Headline
Ophthalmology venture grabs investors’ attention, raises $330 million - statnews.com
About
Ollin Biosciences is developing treatments for eye diseases, specifically targeting conditions like diabetic macular edema and wet age-related macular degeneration. The company has raised $330 million in Series B funding to support its upcoming Phase 3 trial, making it one of the largest funding rounds for a biotech company in recent years.
Article summary
Ophthalmology venture grabs investors’ attention, raises $330 million statnews.com
Investors · 2
TCGXLead
FUND
ARCH Venture Partners
FUND
Related rounds
| Jun 24, 2026 | Cambrian Network | $6.0M | Seed | United States |
| Jun 24, 2026 | Cambrian | $6.0M | Series A | United States |
| Jun 24, 2026 | Taktile | $110.0M | Series C | United States |
| Jun 24, 2026 | Coval | $28.0M | Series A | United States |